Olivier Delattre, MD, PhD was trained in pediatric oncology and in genetics. His research area mainly investigates the genetic and biology of pediatric cancers. His laboratory has identified the genetic alterations of a variety of childhood cancers including the EWS-FLI1 rearrangement in Ewing sarcoma, the SMARCB1 inactivation in rhabdoid tumors, the ALK activation mutation in neuroblastoma and the BCOR-CCNB1 fusion in Ewing-like sarcoma. He has also contributed identifying major tumor predisposing mutations or genetic susceptibility factors in neurofibromatosis type II, rhabdoid syndrome predisposition, neuroblastoma and Ewing sarcoma. His lab has also strong interest in deciphering the cellular origin of pediatric cancers and particularly Ewing sarcoma, neuroblastoma and rhabdoid tumors and in finding new therapeutic targets in these diseases. Olivier Delattre is a member of EMBO since 2011 and of Academia Europea since 2012.
Olivier Delattre is Director of the Cancer, Heterogeneity, Instability and Plasticity department Inserm U830 and Director of the SIREDO center, a pediatric center that gathers researchers and physicians in the oncopaediatrics, adolescent and young adult fields to bring new medications to patients as quickly as possible.